CHOP researchers have identified six biomarkers in the breath of children with COVID-19, laying the groundwork for a potential breathalyzer test.
Read a case study about a patient treated by physicians from the Pancreatic Disorders Program.
A new study involving CHOP researchers show blinatumomab is less toxic and as good or better than chemotherapy for high-risk relapsed B-ALL.
In May 2020, the U.S. Centers for Disease Control and Prevention (CDC) defined multi-system inflammatory syndrome in children (MIS-C), which was the diagnosis in this case.
Study is first to demonstrate how one specific combinational therapy may provide measurable benefits to patients with mitochondrial respiratory chain disorders, which currently lack FDA-approved therapies.
CHOP researchers describe different types of rashes they have seen in patients diagnosed with the COVID-19-related inflammatory syndrome.
CHOP researchers have found that NTRK fusions are more common than expected in pediatric tumors, which could lead to better screening and treatment.
CHOP and Penn Researchers Identify Nanoparticles that Could Be Used in Therapeutic mRNA Delivery before Birth
In a proof-of-concept study, CHOP and Penn researchers have identified ionizable lipid nanoparticles that could be used to deliver mRNA as part of fetal therapy.